What’s wrong in govt consulting industry for policies?

  Last week the famous whistle blower in Ranbaxy data fudging case wrote in Scroll that the Indian drug regulator is “inept” in regulating biosimilars, a new class of drugs that have come to dominate the market and will increasingly do so for the next decade.   Dinesh Thakur certainly has a point but it […]

Yet another Accelerator: Will EVA be a gatekeeper or a gateway?

  Most things associated with start-ups lend themselves to a bubble situation at some point in time. If it was e-commerce in recent times, bioinformatics, medical transcription and virtualisation a few years ago, it’s the accelerators themselves which today run the risk of getting pricked. More than 40 accelerators have come up in the last […]